November 23, 2022
1 min read
Save
INVICTUS
Issue: November 2022

Vitamin K antagonist vs. rivaroxaban (Xarelto, Janssen/Bayer) for reducing rate of ischemic stroke and mortality in adults with rheumatic heart disease-associated atrial fibrillation.